I guess you're right on the "meta-analysis of a subgroup" issue, but perhaps an ADAS-Cog change of >=3 for solanezumab in the prespecified secondary analysis of pooled mild along with MRI and biomarkers, could give them a shot with the FDA considering the highly unmet need and the good safety profile. A 3 point change seems quite hypothetical though...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.